Press Releases

Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, New Jersey, June 1, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will present a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference, being held on June 6-9, 2017 at The Grand Hyatt in New York City.

Foamix logo

Foamix Pharmaceuticals Presentation Details

Date:               Tuesday, June 6, 2017

Time:               04:00 pm Eastern Time

Location:         The Grand Hyatt in New York City, NY, USA

Webcast:        http://wsw.com/webcast/jeff105/fomx          

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

 

Contact:

US Investor Relations

Dorit Hayon

Michael Rice

Foamix Pharmaceuticals Ltd.

LifeSci Advisors, LLC

+972-8-9316233

646-597-6979

IR@foamixpharma.com  

mrice@lifesciadvisors.com

 

SOURCE Foamix Pharmaceuticals Ltd.